The $101M+ XPRIZE Healthspan and ARPA-H PROSPR are two major funding opportunities for Longevity Biotechnology (LongBio) companies that are researching and developing interventions to extend healthspan and healthy longevity. XPRIZE and ARPA-H PROSPR seek to incentivize the translation of biological science into product candidates with clinical evidence showing delay or reversal of physical frailty, cognitive decline, immune resilience decline and related loss of function due to aging.

Applicants and their peers focus on preclinical and clinical development. The translation between preclinical and clinical investigation is subject to review and authorization by the FDA, with its application of regulatory (as distinct from natural) science requirements for nonclinical, Chemistry, Manufacturing and Controls (CMC) and clinical data.

Speakers at this Webinar are:

• Alexander Fleming
• David M. Fox
• Marianne Mann
• Joy Cavagnaro
• Keith Watson